Please Wait
Applying Filters...
menu
    • menu
    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-03-23

    Virtual Booth

    An Enquiry

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    An Enquiry

    Menu

    GADOLINIUM [WHO-DD]

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    $ API Ref.Price (USD/KG) : 1,483Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Briumvi Cuts Relapse And MRI Activity In Active RMS Study
    Briumvi Cuts Relapse And MRI Activity In Active RMS Study

    09 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/09/3251730/8790/en/Data-Published-in-Neurology-and-Therapy-Demonstrate-Significant-Reductions-in-Relapse-and-MRI-Activity-with-BRIUMVI-in-People-with-Highly-Active-Relapsing-Multiple-Sclerosis.html

    GLOBENEWSWIRE
    09 Mar 2026
    Share Share
    Zenas Biopharma Presents Phase 2 Obexelimab Results In Relapsing
    Zenas Biopharma Presents Phase 2 Obexelimab Results In Relapsing

    09 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/09/3234414/0/en/Zenas-BioPharma-Announces-Late-Breaking-Platform-Presentation-of-Results-from-Phase-2-MoonStone-Trial-of-Obexelimab-in-Relapsing-Multiple-Sclerosis-at-ACTRIMS-Forum-2026.html

    GLOBENEWSWIRE
    09 Feb 2026
    Share Share
    EU Approves Guerbet's Half-Dose Elucirem for Kids
    EU Approves Guerbet's Half-Dose Elucirem for Kids

    27 Jan 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/new-indication-in-children-from-birth-for-guerbets-half-dose-gbca-elucirem-gadopiclenol-approved-by-european-commission-302671258.html

    PR NEWSWIRE
    27 Jan 2026
    Share Share
    Hyperfine Enrolls First Patient To Expand Swoop System Use
    Hyperfine Enrolls First Patient To Expand Swoop System Use

    15 Jan 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260115207956/en/Hyperfine-Announces-Enrollment-of-First-Patient-in-Study-to-Expand-Intended-Use-of-the-Swoop-System-with-Contrast-Agents

    BUSINESSWIRE
    15 Jan 2026
    Share Share
    Bayer's Gadoquatrane Meets Key Endpoints in Kids' Study at RSNA25
    Bayer's Gadoquatrane Meets Key Endpoints in Kids' Study at RSNA25

    03 Dec 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251203017985/en/RSNA25-Pediatric-Study-for-Bayers-Investigational-MRI-Contrast-Agent-Gadoquatrane-Meets-Primary-and-Secondary-Endpoints

    BUSINESSWIRE
    03 Dec 2025
    Share Share
    Zenas Autoimmune Drug Prompts 95% Drop In Lesions In MS Study
    Zenas Autoimmune Drug Prompts 95% Drop In Lesions In MS Study

    27 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/27/3174445/0/en/Zenas-BioPharma-Announces-Positive-Results-from-Phase-2-MoonStone-Trial-of-Obexelimab-in-Relapsing-Multiple-Sclerosis.html

    GLOBENEWSWIRE
    27 Oct 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.